Pharming Group
PHGN
Company Profile
Business description
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
Contact
Darwinweg 24
LeidenZH2333 CR
NLDT: +31 715247400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
382
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,696.30 | 62.90 | 0.73% |
| CAC 40 | 7,906.40 | 51.48 | 0.66% |
| DAX 40 | 21,505.70 | 77.46 | 0.36% |
| Dow JONES (US) | 44,556.04 | 134.13 | 0.30% |
| FTSE 100 | 8,570.77 | 12.79 | -0.15% |
| HKSE | 20,647.03 | 142.93 | -0.69% |
| NASDAQ | 19,654.02 | 262.06 | 1.35% |
| Nikkei 225 | 38,834.13 | 35.76 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,037.88 | 43.31 | 0.72% |
| S&P/ASX 200 | 8,428.70 | 54.70 | 0.65% |
| SSE Composite Index | 3,238.85 | 11.75 | -0.36% |